India’s anti-obesity drug market is at an inflection point, with multiple GLP-1–based therapies entering within months in 2025. Global launches like Mounjaro and Wegovy, along with rising off-label use of oral semaglutide, have triggered a surge in demand. As Indian pharma prepares for generic launches in 2026, the segment is set for intense competition, falling prices and wider access.